trending Market Intelligence /marketintelligence/en/news-insights/trending/pYV3ZK0tOa5e38-mdTdu_w2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Dr. Reddy's, Perrigo join in recall of ranitidine over impurity

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Dr. Reddy's, Perrigo join in recall of ranitidine over impurity

India's Dr. Reddy's Laboratories Ltd. initiated a voluntary recall of its ranitidine medicines in the U.S. market due to the confirmed contamination of a potential cancer-causing impurity called N-Nitrosodimethylamine, or NDMA.

The Indian drugmaker said in an Oct. 23 press release that the recall — which was initiated Oct. 1 — follows a warning issued by the U.S. Food and Drug Administration in September regarding the presence of NDMA in ranitidine, which is used to treat heartburn associated with acid indigestion and sour stomach.

Dr. Reddy's added that it has not received any reports of adverse events related to the recall of the company's ranitidine products.

Dr. Reddy's is the latest in a line of drugmakers to pull ranitidine medications off the shelves. Sanofi, which markets ranitidine as Zantac, has recalled the medicine in the U.S. and Canada, while Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Mylan NV and Novartis AG have also recalled their generic ranitidine medicines following concerns expressed by the U.S. FDA, Health Canada and the European Medicines Agency.

Later on Oct. 23, Perrigo Company PLC also announced a worldwide recall of its ranitidine products due to the NDMA impurity. The Irish company said it began testing its ranitidine products after the FDA and other regulators flagged the concern, halting shipments Oct. 8. Perrigo has now opted to move forward with a recall based on the data collected.